GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Frontage Holdings Corp (HKSE:01521) » Definitions » Research & Development

Frontage Holdings (HKSE:01521) Research & Development : HK$47 Mil (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Frontage Holdings Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Frontage Holdings's Research & Development for the six months ended in Dec. 2023 was HK$23 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was HK$47 Mil.

Frontage Holdings Research & Development Historical Data

The historical data trend for Frontage Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Frontage Holdings Research & Development Chart

Frontage Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial 11.94 14.27 18.98 30.24 47.16

Frontage Holdings Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.46 12.45 17.89 24.57 22.66

Frontage Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$47 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frontage Holdings  (HKSE:01521) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Frontage Holdings Research & Development Related Terms

Thank you for viewing the detailed overview of Frontage Holdings's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Frontage Holdings (HKSE:01521) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Frontage Holdings Corp (HKSE:01521) » Definitions » Research & Development
Comparable Companies
HKSE:02257 HKSE:01167 HKSE:01477 HKSE:02179 HKSE:02616 HKSE:01244 HKSE:01873 HKSE:06622 HKSE:02171 HKSE:02496 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
FGHQF:USA
Address
700 Pennsylvania Drive, Exton, PA, USA, 19341
Website
https://www.frontagelab.com
Frontage Holdings Corp is a contract research organization providing integrated, scientifically driven research, analytical and development services. Geographically the group operates in both PRC and North America. The services provided in the North American segment, include Bioanalytical, CMC, DMPK and Safety and Toxicology services in the USA and Canada. The service offered in PRC includes Bioanalytical, Bioequivalence and CMC services in the PRC. Further, it also provides bioanalytical services, which are offered throughout the drug discovery and development process both in the United States and China.

Frontage Holdings (HKSE:01521) Headlines

No Headlines